Home Ideas & Research Indexes Hedge Funds Portfolios My tickerspy Newswire
Enter ticker(s) QQQ: 74.16 -0.15%   SPY: 167.29 +0.07%
Discuss Index Tracked By  


  Track the *RXCAN Index  

Cancer Stocks (*RXCAN)

  Cancer Ideas       Cancer Performance       Cancer Community  
 
Popular long ideas:
Popular short ideas:
Top dividend plays:
Pro favorites:
DNDN, CTIC, GERN
DNDN, CTIC, BCRX
PDLI
ONXX, HSP, REGN
 
Index Description: These medical firms have significant exposure to cancer detection and treatment
     
Today:
1-month:
All-time:
+0.9%
+0.5%
+18.1%
vs S&P 500:
vs S&P 500:
vs S&P 500:
+0.8%
-6.6%
-3.0%
Data since: Jan-01-2008
 
Avg. Market Cap:
Avg. P/E Ratio:
Avg. Div Yield:
$2.2B
18.0
0.2%
     
229 members Tracking
Share this Index on Facebook
Share this Index on Twitter
 
                     
     
 
Chart View
1 week
 
1 month
 
3 months
 
6 months
 
All Time
 
 
 
 
 
 
 
   
     
 
Portfolio Detail
 
  Standard View     Performance View     Ideas & Research    
Click a column to sort | Scroll over columns for more information
 
 Ticker Last Trade Today's Change Volume  % of
Daily
Mkt Cap  Div Yield  % off
52wk lw
% from
52wk hg
Alerts
 GNBT $0.03 0.00 +11.7% 4,514,138 539% $19.4M - 49% -73% No Alerts/News
 GTXI $6.73 +0.38 +6.0% 1,261,014 452% $399.3M - 157% 5% 4 Alerts (0 News) - View
 CTIC $1.27 -0.05 -3.8% 1,530,204 282% $148.6M - 25% -76% 1 Alert (0 News) - View
 ARIA $18.81 +1.28 +7.3% 6,138,244 278% $3.2B - 24% -26% 3 Alerts (0 News) - View
 MSTX $0.66 +0.01 +1.6% 333,931 265% $30.0M - 47% -28% No Alerts/News
 CYCC $2.96 -0.10 -3.4% 432,578 237% $33.2M - 1% -64% 4 Alerts (1 News) - View
 PPHM $1.62 -0.04 -2.4% 2,593,740 136% $222.0M - 284% -71% 1 Alert (0 News) - View
 ONXX $93.65 +0.74 +0.8% 918,593 108% $6.7B - 127% -8% 1 Alert (0 News) - View
 MEIP $8.43 -0.05 -0.6% 58,608 105% $127.5M - 326% -36% No Alerts/News
 AEZS $2.04 -0.04 -2.1% 163,492 101% $52.6M - 20% -64% No Alerts/News
 MYGN $32.51 -0.50 -1.5% 912,264 92% $2.6B - 48% -6% No Alerts/News
 PDLI $8.37 0.00 0.0% 1,076,588 79% $1.1B 7.2% 35% -1% 1 Alert (0 News) - View
 CVM $0.25 -0.01 -2.2% 620,879 79% $79.7M - 23% -55% No Alerts/News
 ONTY $1.97 -0.03 -1.5% 599,908 70% $114.4M - 15% -68% 2 Alerts (0 News) - View
 QLTI $7.93 0.00 0.0% 36,102 69% $400.6M - 25% -13% No Alerts/News
 SGEN $35.61 -0.12 -0.3% 383,963 63% $4.3B - 87% -9% No Alerts/News
 REGN $263.43 +3.47 +1.3% 748,598 61% $25.4B - 145% -7% 2 Alerts (1 News) - View
 ARRY $5.96 +0.08 +1.4% 584,161 59% $686.1M - 99% -9% No Alerts/News
 AVEO $2.76 -0.14 -4.8% 1,436,002 55% $150.3M - 23% -80% 2 Alerts (0 News) - View
 EXEL $4.60 -0.01 -0.2% 648,024 53% $847.2M - 10% -34% No Alerts/News
 GERN $1.12 0.00 0.0% 261,384 52% $146.0M - 23% -63% No Alerts/News
 KERX $7.98 -0.07 -0.9% 905,223 50% $657.8M - 415% -20% 1 Alert (0 News) - View
 MELA $1.10 +0.01 +0.9% 183,512 48% $46.9M - 8% -75% No Alerts/News
 UTHR $68.03 -0.44 -0.6% 267,779 45% $3.4B - 63% -2% 1 Alert (0 News) - View
 DNDN $3.99 +0.03 +0.8% 1,586,491 43% $624.7M - 8% -50% No Alerts/News
 ISIS $21.04 +0.23 +1.1% 442,824 33% $2.1B - 178% -9% 1 Alert (0 News) - View
 HSP $35.71 -0.21 -0.6% 334,339 33% $5.9B - 25% -5% No Alerts/News
 XOMA $4.14 -0.04 -1.0% 174,805 30% $346.4M - 84% -6% No Alerts/News
 VRTX $79.23 -0.24 -0.3% 749,815 29% $17.3B - 106% -9% No Alerts/News
 PGNX $3.97 -0.05 -1.2% 71,338 29% $205.1M - 182% -64% 1 Alert (0 News) - View
 DCTH $0.42 -0.02 -4.4% 644,842 25% $39.9M - 12% -83% 1 Alert (0 News) - View
 CYTK $1.14 -0.01 -0.9% 316,214 24% $168.4M - 100% -22% No Alerts/News
 BCRX $1.71 +0.01 +0.6% 329,136 24% $87.3M - 58% -65% No Alerts/News
 ENZN $3.11 -0.03 -1.0% 73,475 23% $137.2M - 6% -58% No Alerts/News
 TELK $1.38 +0.01 +1.1% 2,120 11% $6.2M - 27% -81% No Alerts/News
Is this index incomplete or incorrect?
Got an idea for a new Index?
 
Latest Portfolio Notes & Links
 
View: Headlines   |   Message Board   |   Portfolio Notes  
 
 
Dupilumab, a New Drug, May Help Some Asthmatics Linked by NYTimes - May 21, 04:12PM - Reply
REGN  SNY  
Cyclacel Pharmaceuticals Announces Closing of Underwritten Offering Linked by GlobeNewswire - May 21, 04:13PM - Reply
CYCC  CYCCP  
$307,000-a-year Vertex Drug: Billions in Sales? Linked by YCHARTS - May 20, 12:50PM - Reply
VRTX  
UK to Pilot Illumina Genetic Test for Breast, Ovarian Cancer Linked by Bloomberg - May 20, 10:07AM - Reply
MYGN  ILMN  
Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Delcath Systems, Inc. of Class Action Lawsuit and Upcoming Deadline -- DCTH Linked by GlobeNewswire - May 17, 05:43PM - Reply
DCTH  
Progenics Pharmaceuticals Added to the NASDAQ Biotechnology Index Linked by GlobeNewswire - May 17, 05:43PM - Reply
PGNX  
Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015 Linked by BusinessWire - May 17, 08:30AM - Reply
VRTX  
Mid-Morning Market Update: Housing Starts Plummet, Initial Jobless Claims Rise Linked by Benzinga.com - May 16, 10:51AM - Reply
AMD  CSCO  HALO  DRYS  ONTY  
Top New Biotech Ideas from PropThink Linked by 24/7 Wall St. - May 16, 07:30AM - Reply
CELG  REGN  CBST  VPHM  ONXX  AVEO  MAKO  
AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trials Linked by Bloomberg - May 16, 02:18AM - Reply
ARRY  
Summary of Jana Partners 13F: Aetna, Expedia and Kinder Morgan All Raised Among Others Linked by Benzinga.com - May 15, 03:24PM - Reply
AIG  BA  KO  SVU  FNP  BIG  ODP  WM  BMC  SYMC  IACI  CPRT  TK  AGU  OPK  VRSN  IRM  CVG  AXL  NFLX  VC  AET  HSP  ASH  ROC  EXPE  LYV  SE  KAR  DTV  LINTA  QEP  SEMG  KMI  GRPN  ZNGA  TRIP  ADT  FANG  LMCA  
Company That Sells Angelina Jolie’s Blood Test Linked by YCHARTS - May 15, 03:18PM - Reply
MYGN  MON  
What We're Reading ~ Analytical Links 5/15/13 Linked by market folly - May 15, 01:05PM - Reply
VZ  VOD  DLTR  HSP  FLT  
Dendreon Gets Prostate Cancer Competition for Provenge from Bayer’s Xofigo Linked by 24/7 Wall St. - May 15, 11:15AM - Reply
DNDN  
Deutsche Bank Firm on Biotech Stocks to Buy Linked by 24/7 Wall St. - May 15, 08:10AM - Reply
AMGN  CELG  REGN  BIIB  VRTX  GILD  ALXN  ONXX  DB  
Mast Therapeutics Reports First Quarter 2013 Financial Results Posted by PR Newswire - May 15, 08:00AM - Reply
MSTX  
Roche Wins FDA Approval for Test to Target Lung Cancer Linked by Bloomberg - May 14, 05:43PM - Reply
MYGN  QGEN  
Myriad Genetics, Angelina Jolie, and Genomics in Focus Linked by 24/7 Wall St. - May 14, 01:58PM - Reply
MYGN  GHDX  ROSG  
Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference Linked by GlobeNewswire - May 14, 07:13AM - Reply
MYGN  
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $150,000 From Investment in AVEO Pharmaceuticals, Inc. to Contact Brower Piven Before the July 8, 2013 Lead Plaintiff Deadline -- AVEO Linked by GlobeNewswire - May 13, 05:43PM - Reply
AVEO  
Page 1 2 3 4 5 6 7 8 9 ... 156



Click to close X

Use portfolios to track tickers you're interested in. News related to your tickers will appear below the portfolio. Tickers in your portfolios will generate Alerts on your tickerspy Alerts page.

The Recent Tickers portfolio saves the tickers you've recently viewed on the site.

Click to close X

By matching similar portfolios, tickerspy helps members find institutional and individual investors with strategies similar to their own.

Click to close X

Portfolio performance for tickerspy member portfolios is calculated by equally weighting all of the stocks held in the portfolio.

Click to close X

Performance View offers a snapshot of how individual portfolio positions have performed since being added (or shorted) as well as a look at the individual stocks' performance over various time periods. In the case of "shorts," a decline in price will result in a positive gain.

Portfolio History offers a view of all current and past holdings in a portfolio.

Click to close X

Institutional Holdings Disclaimer

Pro portfolios track the top 15 quarterly holdings of more than 1,400 institutions. Comments in Pro portfolios show the institution's change in shares held for each company quarter over quarter.

Pro portfolio performance is based on institutions' top 15 holdings as disclosed in quarter-end filings with the SEC. Pro performance does not take into account additional holdings beyond the top 15 nor does it include positions that are not required to be disclosed by the SEC. As such, Pro portfolio performance should be considered an approximation and not a precise record of how an institution has performed over time.

tickerspy is not affiliated with any of the Pro investors profiled on our web site. The performance data and graph are estimates and do not represent an advertisement or endorsement by either tickerspy or the Pro investors.

Click to close X

To calculate "all-time" Pro performance, we combine all of the quarterly holdings reports for that Pro investor. The initial date used is the start date of the first quarterly holdings report we have in our database. Start dates vary based on the first quarterly holdings report we have for each Pro. Please see our Institutional Holdings Disclaimer (located at the bottom of this page) for more on how we calculate Pro portfolio performance estimates. tickerspy is not affiliated with any of Pro investors profiled on our web site.

Click to close X

Your primary portfolio will appear in other member’s Tracking Hubs when they track your performance. Your primary portfolio is also used in our Ideas & Research section, where your portfolio is compared with the portfolios of other members, and elsewhere on the site where other portfolio comparisons are made.

Note: Primary portfolios must contain at least five stocks of greater than $1 per share. If you have elected to make your primary portfolio private or if your portfolio is not eligible to be primary, it will not appear in the Ideas & Research section or on the front page.

Click to close X

Primary portfolio

Click to close X
Click the Alerts links in your portfolio to see news from the last 36 hours as well as data alerts displaying unusual price and volume action. You will also see Alerts related to the activity of other tickerspy members. To see more Alerts, visit your customized Alerts page. And for more Alerts info, visit our Alerts FAQ.
Click to close X
tickerspy Indexes use a "net asset value" calculation. The components are equally weighted at the inception of the Index (typically 1/1/2008) and over time as some stocks go up and others go down, the relative weights of the components shift accordingly.
Click to close X

We look at the recent net stock adds (people adding a stock to their portfolio minus people removing it) and compare against the company's previous history to identify those companies that are seeing the largest changes on a relative basis. Without the company history comparison, our most followed companies would likely be near the top of the list at all times. A value greater than one indicates a greater than normal number of adds over the last seven days, and a value less than one indicates a less than normal number of adds. If no value is shown, there was not enough activity to generate a value.

Click to close X

We look at the recent net stock shorts (people shorting it in their portfolios minus people covering their short) and compare against the company's previous history to identify those companies that are seeing the largest changes on a relative basis. A value less than -1 (for example -3.6) indicates a greater than normal number of shorts over the last seven days, and a value greater than -1 (for example -0.6) indicates a less than normal number of adds. If no value is shown, there was not enough activity to generate a value.

Click to close X

Thanks for helping us keep tickerspy Indexes accurate!

Let us know which tickers should be added or removed from the Cancer Stocks Index (*RXCAN).

Note: Our tickerspy research team will look at all recommendations but not all of them will be implemented. As a general rule, stocks with a market cap below $50 million will not be included.


Click to close X

Got an idea for an Index we don't have listed? Send it, and our research team will consider it for inclusion.

Note: Our tickerspy research team look at all recommendations but not all of them will be implemented. As a general rule, stocks with a market cap below $50 million will not be included.

Index Name

Tickers(separate with spaces or commas)

Additional comments